SG11201807148RA - Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions - Google Patents

Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions

Info

Publication number
SG11201807148RA
SG11201807148RA SG11201807148RA SG11201807148RA SG11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA SG 11201807148R A SG11201807148R A SG 11201807148RA
Authority
SG
Singapore
Prior art keywords
epha2
docetaxel
international
massachusetts
immunoliposomes
Prior art date
Application number
SG11201807148RA
Inventor
Daryl C Drummond
Dmitri B Kirpotin
Zhaohua R Huang
Suresh K Tipparaju
Charles Noble
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of SG11201807148RA publication Critical patent/SG11201807148RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 September 2017 (21.09.2017) WIPO I PCT (10) International Publication Number WO 2017/161067 Al 111111111111110111010101111101011111011101111111101011011001111111111111110111111 (51) International Patent Classification: A61K 47/69 (2017.01) (21) International Application Number: PCT/US2017/022624 (22) International Filing Date: 16 March 2017 (16.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/309,222 16 March 2016 (16.03.2016) US 62/322,940 15 April 2016 (15.04.2016) US 62/338,052 18 May 2016 (18.05.2016) US 62/419,012 8 November 2016 (08.11.2016) US 62/464,538 28 February 2017 (28.02.2017) US (71) Applicant: MERRIMACK PHARMACEUTICALS, INC [US/US]; One Kendall Square, Suite B7201, Cam- bridge, Massachusetts 02139 (US). (72) Inventors: DRUMMOND, Daryl C.; 1 Brooks Road, Lin- coln, Massachusetts 01773 (US). KIRPOTIN, Dmitri B.; 382 Ocean Avenue, Apt. 1509, Revere, Massachusetts 02151 (US). HUANG, Zhaohua R.; 2115 Washington Street, Braintree, Massachusetts 02184 (US). TIPPAR- AJU, Suresh K.; 48 Epping Street, Arlington, Massachu- setts 02474 (US). NOBLE, Charles; 990 Carolina St, San Francisco, California 94158 (US). (74) Agent: DAY, Noel E.; Honigman Miller Schwartz & Cohn LLP, 350 East Michigan Avenue, Suite 300, Kalamazoo, Michigan 49007 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 16 1067 Al (54) Title: EPHRIN RECEPTOR A2 (EPHA2)-TARGETED DOCETAXEL-GENERATING NANO-LIPOSOME COMPOSI- TIONS (57) : EphA2-targeted immunoliposomes for delivering docetaxel are useful in the treatment of certain types of cancer. The immunoliposomes can include an EphA2 targeting moiety (e.g., a scFv) and encapsulate a docetaxel prodrug in a stable salt form within a liposome having an average size of about 100 nm. Novel docetaxel prodrugs suitable for loading into nanoliposomes (in - cluding immunoliposomes) are provided, along with novel and other useful EphA2 targeting moieties for preparation of EphA2-tar - geted doxorubicin-generating immunoliposome therapies. Pharmaceutical compositions can be prepared that include nanoliposomes encapsulating one or more docetaxel prodrugs, and/or immunoliposomes or nanoparticles comprising an EphA2 binding moiety and encapsulating one or more docetaxel prodrugs. The pharmaceutical compositions are useful for administration to a patient for the treatment of cancer.
SG11201807148RA 2016-03-16 2017-03-16 Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions SG11201807148RA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662309222P 2016-03-16 2016-03-16
US201662322940P 2016-04-15 2016-04-15
US201662338052P 2016-05-18 2016-05-18
US201662419012P 2016-11-08 2016-11-08
US201762464538P 2017-02-28 2017-02-28
PCT/US2017/022624 WO2017161067A1 (en) 2016-03-16 2017-03-16 Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions

Publications (1)

Publication Number Publication Date
SG11201807148RA true SG11201807148RA (en) 2018-09-27

Family

ID=58461461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807148RA SG11201807148RA (en) 2016-03-16 2017-03-16 Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions

Country Status (12)

Country Link
US (1) US20180021294A1 (en)
EP (1) EP3429629A1 (en)
JP (1) JP2019508434A (en)
KR (1) KR20180121904A (en)
CN (1) CN109310782A (en)
AU (1) AU2017232632A1 (en)
BR (1) BR112018068000A2 (en)
CA (1) CA3016455A1 (en)
IL (1) IL261276A (en)
SG (1) SG11201807148RA (en)
TW (1) TW201804987A (en)
WO (1) WO2017161067A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103168104B (en) * 2010-07-22 2016-09-28 加利福尼亚大学董事会 Antitumor-antigen antibody and using method thereof
CN108778328A (en) * 2016-03-16 2018-11-09 加利福尼亚大学董事会 Albumin A combination polypeptide, anti-EPHA 2 antibody and its application method
WO2018160794A1 (en) 2017-03-01 2018-09-07 Merrimack Pharmaceuticals, Inc. Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulatory t cell activity for treating cancer
KR20220159289A (en) 2021-05-25 2022-12-02 주식회사 박셀바이오 Monobody based chimeric antigen receptor and immune cell comprising thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
KR101462825B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
CN103168104B (en) * 2010-07-22 2016-09-28 加利福尼亚大学董事会 Antitumor-antigen antibody and using method thereof
CN103479578B (en) * 2012-06-14 2016-08-03 沈阳药科大学 The Liposomal formulation of a kind of maleic acid Pixantrone and preparation technology thereof
CA2903255C (en) * 2013-03-13 2018-08-28 Mallinckrodt Llc Modified docetaxel liposome formulations

Also Published As

Publication number Publication date
US20180021294A1 (en) 2018-01-25
IL261276A (en) 2018-10-31
BR112018068000A2 (en) 2019-02-05
AU2017232632A1 (en) 2018-09-13
EP3429629A1 (en) 2019-01-23
CA3016455A1 (en) 2017-09-21
KR20180121904A (en) 2018-11-09
CN109310782A (en) 2019-02-05
TW201804987A (en) 2018-02-16
WO2017161067A1 (en) 2017-09-21
JP2019508434A (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG11201901126UA (en) Combination therapy for cancer
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201807148RA (en) Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201811237WA (en) Combination therapies
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201407349UA (en) Proliposomal testosterone formulations
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201903431SA (en) Sstr-targeted conjugates and particles and formulations thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201809751XA (en) Egfr inhibitor compounds
SG11201903889TA (en) Crenolanib for treating flt3 mutated proliferative disorders associated mutations
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers